Micafungin Pharmazac (Micafungin)

• Micafungin is an echinocandin antifungal used to treat invasive Candida infections and related conditions, including severe forms.
• Invasive candidiasis: clears bloodstream and deep‑tissue Candida infections, improving survival in critically ill patients.
• Esophageal candidiasis: eradicates Candida overgrowth in the esophagus, relieving pain and dysphagia.
• Candida peritonitis: treats intra‑abdominal Candida infection, supporting recovery after abdominal surgery.
• Febrile neutropenia: used as empirical therapy in neutropenic patients with fever to cover possible Candida infection.

• Micafungin inhibits the enzyme β‑1,3‑D‑glucan synthase, which is essential for synthesizing 1,3‑β‑D‑glucan, a key structural component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell lysis without affecting human cells.

Micafungin may cause a range of adverse reactions, most of which are manageable.

Common Side Effects

• Infusion‑related reactions such as flushing or chills.
• Fever or chills during or after infusion.
• Nausea or vomiting.
• Elevated liver enzymes (ALT, AST).
• Headache.
• Rash or mild skin irritation.

Serious or Rare Side Effects

• Severe hepatic dysfunction or hepatitis.
• Anaphylaxis or severe hypersensitivity reactions.
• Acute renal failure.
• Severe hypotension or cardiovascular collapse.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cytopenias (e.g., neutropenia, thrombocytopenia).

• Use of Micafungin requires careful clinical monitoring.
• Renal function: assess baseline renal status and monitor during therapy.
• Hepatic function: check liver enzymes before initiation and periodically thereafter.
• Concomitant antifungals: avoid overlapping use with other echinocandins or azoles unless clinically justified.
• Pregnancy and lactation: prescribe only if potential benefit outweighs potential risk.
• Drug interactions: review all concomitant medications for possible interactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• Co‑administration with strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure.
• Concurrent use with other echinocandins increases risk of additive toxicity.
• Combination with azole antifungals may heighten hepatotoxic potential.

Moderate Interactions (Monitor Closely)

• Cyclosporine may increase micafungin plasma concentrations; monitor cyclosporine levels.
• Warfarin therapy may be affected; check INR regularly.
• Use with nephrotoxic agents (e.g., aminoglycosides) warrants renal function monitoring.